BioCentury
ARTICLE | Company News

IFM launches subsidiary for cGAS, STING inhibitors

February 11, 2019 8:26 PM UTC

IFM Therapeutics LLC (Boston, Mass.) launched IFM Due Inc., a subsidiary that intends to develop inhibitors of cGAS and STING to treat autoimmune and inflammatory diseases. The subsidiary also named immunologist Andrea Ablasser, a professor at the École Polytechnique Fédérale de Lausanne, as its founding scientist.

The subsidiary is the second that IFM Therapeutics has launched since it was established to house programs that were not acquired by Bristol-Myers Squibb Co. (NYSE:BMS) in its takeout of original parent company IFM Therapeutics Inc. in 2017. In that deal, BMS obtained activators of STING and NLRP3 to treat cancer; the biotech's shareholders received $300 million up front (see "The Flip-Side of Immunotherapy")...